Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 518,427 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,546 shares during the period. Dimensional Fund Advisors LP owned about 4.37% of ANI Pharmaceuticals worth $23,339,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in the company. South Dakota Investment Council acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter worth about $45,000. Municipal Employees Retirement System of Michigan acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter worth about $115,000. Metropolitan Life Insurance Co. NY grew its position in ANI Pharmaceuticals by 324.2% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,872 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 2,195 shares during the period. Oregon Public Employees Retirement Fund acquired a new position in ANI Pharmaceuticals during the fourth quarter worth about $142,000. Finally, Texas Permanent School Fund grew its position in ANI Pharmaceuticals by 4.3% during the fourth quarter. Texas Permanent School Fund now owns 5,427 shares of the specialty pharmaceutical company’s stock worth $244,000 after buying an additional 222 shares during the period. 63.92% of the stock is owned by institutional investors and hedge funds.
Several research analysts have weighed in on the stock. ValuEngine upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $77.00 target price on the stock in a research report on Thursday, May 16th. BidaskClub lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 11th. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 price target (up previously from $80.00) on shares of ANI Pharmaceuticals in a report on Monday, May 13th. Finally, Raymond James downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and upped their price target for the company from $73.00 to $82.00 in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $84.50.
NASDAQ:ANIP traded up $0.48 during trading hours on Wednesday, reaching $78.42. 192,431 shares of the company were exchanged, compared to its average volume of 103,887. The company has a current ratio of 0.92, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33. The stock has a market cap of $932.55 million, a price-to-earnings ratio of 17.01 and a beta of 2.24. ANI Pharmaceuticals Inc has a 52-week low of $36.92 and a 52-week high of $80.30. The company’s 50 day moving average is $71.34.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.25. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The company had revenue of $52.90 million during the quarter, compared to analyst estimates of $50.57 million. During the same quarter in the prior year, the business earned $1.32 earnings per share. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. On average, analysts forecast that ANI Pharmaceuticals Inc will post 5.57 EPS for the current fiscal year.
In other ANI Pharmaceuticals news, Director David Nash acquired 1,445 shares of the stock in a transaction dated Friday, May 24th. The shares were bought at an average price of $68.76 per share, with a total value of $99,358.20. Following the purchase, the director now directly owns 5,236 shares of the company’s stock, valued at approximately $360,027.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Arthur Przybyl sold 30,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total transaction of $2,102,100.00. Following the completion of the transaction, the insider now directly owns 222,994 shares in the company, valued at approximately $15,625,189.58. The disclosure for this sale can be found here. Insiders sold 50,911 shares of company stock valued at $3,585,114 in the last three months. Company insiders own 24.70% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Further Reading: What is Cost of Debt?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.